AI assistant
Dechra Pharmaceuticals PLC Director's Dealing 2020
4797_dirs_2020-12-03_d40eb5f8-bf94-411c-8bea-01f0f2897448.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 4345H
Dechra Pharmaceuticals PLC
03 December 2020
3 December 2020
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
LEI: 213800J4UVB5OWG8VX82
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Exercise of SAYE options:
Dechra Pharmaceuticals PLC announces that on 2 December 2020 Ian Page (PDMR) exercised options, under the Dechra Pharmaceuticals PLC Save As Year Earn Scheme, over 1,093 ordinary shares of 1p each (Ordinary Shares) at an exercise price of £16.46 per share.
Following this acquisition, Ian Page's beneficial interest in the Company is 340,012 shares (0.314% of the current issued share capital).
Dechra Pharmaceuticals PLC announces that on 2 December 2020 Paul Sandland (PDMR) exercised options, under the Dechra Pharmaceuticals PLC Save As Year Earn Scheme, over 1,093 ordinary shares of 1p each (Ordinary Shares) at an exercise price of £16.46 per share. He subsequently transferred the shares to his spouse, Adele Sandland for nil cost.
Following this acquisition, Paul Sandland's beneficial interest in the Company is 7,611 shares (0.007% of the current issued share capital).
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Forms
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Ian Page | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Exercise of 1,093 options under the Company's Save As You Earn Scheme | |
| c) | Price(s) and volumes(s) | Price(s) £16.46 |
Volume(s) 1,093 |
| d) | Aggregated information - Aggregate volume - Price |
1,093 £17,990.78 |
|
| e) | Date of the transaction | 2020.12.2 | |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Paul Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Exercise of 1,093 options under the Company's Save As You Earn Scheme | |
| c) | Price(s) and volumes(s) | Price(s) £16.46 |
Volume(s) 1,093 |
| d) | Aggregated information - Aggregate volume - Price |
1,093 £17,990.78 |
|
| e) | Date of the transaction | 2020.12.2 | |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Paul Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Transfer of 1,093 Ordinary Shares to his spouse for nil cost | |
| c) | Price(s) and volumes(s) | Price(s) £0 |
Volume(s) 1,093 |
| d) | Aggregated information - Aggregate volume - Price |
1,093 £0 |
|
| e) | Date of the transaction | 2020.12.02 | |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Adele Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Person Close Associated with Paul Sandland (Director/PDMR) | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Receipt of 1,093 Ordinary Shares from her spouse for nil cost | |
| c) | Price(s) and volumes(s) | Price(s) £0 |
Volume(s) 1,093 |
| d) | Aggregated information - Aggregate volume - Price |
1,093 £0 |
|
| e) | Date of the transaction | 2020.12.02 | |
| f) | Place of the transaction | Outside a trading venue |
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKKNBQCBDKKBK